Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia

AIMS: The aim of the phase Ib, two part SAWYER study (BO25341; NCT01292603) was to investigate the pharmacokinetics and safety of subcutaneous (s.c.) rituximab compared with intravenous (i.v.) rituximab, both in combination with fludarabine and cyclophosphamide (FC), as first line treatment for pati...

Full description

Saved in:
Bibliographic Details
Published in:Br J Clin Pharmacol
Main Authors: Assouline, Sarit, Buccheri, Valeria, Delmer, Alain, Gaidano, Gianluca, McIntyre, Christine, Brewster, Michael, Catalani, Olivier, Hourcade-Potelleret, Florence, Sayyed, Pakeeza, Badoux, Xavier
Format: Artigo
Language:Inglês
Published: John Wiley & Sons, Ltd 2015
Subjects:
Clinical Trials
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4631173/
https://ncbi.nlm.nih.gov/pubmed/25900065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12662
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items